BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 20570927)

  • 1. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
    Zhang W; Zhu XD; Sun HC; Xiong YQ; Zhuang PY; Xu HX; Kong LQ; Wang L; Wu WZ; Tang ZY
    Clin Cancer Res; 2010 Jul; 16(13):3420-30. PubMed ID: 20570927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
    Wang Z; Zhou J; Fan J; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Clin Cancer Res; 2008 Aug; 14(16):5124-30. PubMed ID: 18698030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
    Man K; Ng KT; Xu A; Cheng Q; Lo CM; Xiao JW; Sun BS; Lim ZX; Cheung JS; Wu EX; Sun CK; Poon RT; Fan ST
    Clin Cancer Res; 2010 Feb; 16(3):967-77. PubMed ID: 20103676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the inhibitory effect of small tripeptide CMS024 on tumor growth and metastasis in nude mice model of human hepatocellular carcinoma metastasis].
    Li Y; Tang ZY; Wang L; Yao Z; Lu R; Xue Q; Gao DM; Chen J
    Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(8):675-9. PubMed ID: 15130313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
    Blivet-Van Eggelpoël MJ; Chettouh H; Fartoux L; Aoudjehane L; Barbu V; Rey C; Priam S; Housset C; Rosmorduc O; Desbois-Mouthon C
    J Hepatol; 2012 Jul; 57(1):108-15. PubMed ID: 22414764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells.
    Zhang T; Sun HC; Zhou HY; Luo JT; Zhang BL; Wang P; Wang L; Qin LX; Ren N; Ye SL; Li Q; Tang ZY
    Cancer Lett; 2010 Apr; 290(2):204-10. PubMed ID: 19822391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma.
    Esposito V; Palescandolo E; Spugnini EP; Montesarchio V; De Luca A; Cardillo I; Cortese G; Baldi A; Chirianni A
    Clin Cancer Res; 2006 Apr; 12(8):2634-9. PubMed ID: 16638877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein.
    Zhang D; Li B; Shi J; Zhao L; Zhang X; Wang C; Hou S; Qian W; Kou G; Wang H; Guo Y
    Cancer Res; 2010 Mar; 70(6):2495-503. PubMed ID: 20197464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chitosan nanoparticles inhibit the growth of human hepatocellular carcinoma xenografts through an antiangiogenic mechanism.
    Xu Y; Wen Z; Xu Z
    Anticancer Res; 2009 Dec; 29(12):5103-9. PubMed ID: 20044623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.
    Aharinejad S; Paulus P; Sioud M; Hofmann M; Zins K; Schäfer R; Stanley ER; Abraham D
    Cancer Res; 2004 Aug; 64(15):5378-84. PubMed ID: 15289345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice].
    Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY
    Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
    Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
    Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of Rapamycin on angiogenesis and tumor progression in human hepatocellular carcinoma implantation mice].
    Zhang J; Li H; Wang GS; Jiang N; Yang Y; Chen GH
    Zhonghua Wai Ke Za Zhi; 2009 Sep; 47(18):1403-5. PubMed ID: 20092777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vasoinhibitory effect of daltepartin sodium on human hepatocellular carcinoma in nude mice].
    Yan J; Zheng Q; Wang Y; Lu HF; Xue Q; Tang ZY
    Zhonghua Gan Zang Bing Za Zhi; 2005 May; 13(5):359-61. PubMed ID: 15918971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of thalidomide on tumor growth in mouse hepatoma H22 model].
    Zhai Y; Lu ZJ
    Ai Zheng; 2003 Dec; 22(12):1301-6. PubMed ID: 14693056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.